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SUMMARY
The FEZ1/LZTS1 (LZTS1) protein is frequently downregulated in human cancers of different histo-
types. LZTS1 is expressed in normal tissues, and its introduction in cancer cells inhibits cell growth
and suppresses tumorigenicity, owing to an accumulation of cells in G2/M. Here, we define its role in
cell cycle regulation and tumor progression by generating Lzts1 knockout mice. In Lzts1/ mouse
embryo fibroblasts (MEFs), Cdc25C degradation was increased during M phase, resulting in de-
creased Cdk1 activity. As a consequence, Lzts1/ MEFs showed accelerated mitotic progression,
resistance to taxol- and nocodazole-induced M phase arrest, and improper chromosome segrega-
tion. Accordingly, Lzts1 deficiency was associated with an increased incidence of both spontaneous
and carcinogen-induced cancers in mice.INTRODUCTION
During the course of cancer development, a normal cell
progresses toward malignancy by acquiring a specific se-
ries of mutations. Over the past decades, genetic studies
have demonstrated that cancer cells accumulate DNA
changes that activate oncogenes and inactivate tumor-
suppressor genes.
The role of tumor-suppressor genes in neoplasia devel-
opment is crucial, given that reintroduction of one or moreof these genes into cells in which their function is compro-
mised can cause complete reversion to the neoplastic
process (Ichikawa et al., 1994). In light of this, it is not
surprising that many tumors frequently show loss of het-
erozygosity (LOH) at specific chromosomal regions
encompassing tumor-suppressor genes.
One of these regions is located at chromosome 8p22,
which is frequently deleted in breast, lung, gastric, esoph-
ageal, prostate, and bladder cancers (Vocke et al., 1996;
Wagner et al., 1997; Anbazhagan et al., 1998; El-NaggarSIGNIFICANCE
Both entry and exit from mitosis are driven by the modulation of Cdk1 activity, which is finely regulated by several
protein complexes. Knowing the players that control the activity of Cdk1 in each phase of the cell cycle is of pri-
mary importance to fully understand how normal and cancer cells divide. The present data establish Lzts1 as an
important player in ensuring proper Cdk1 activity during M phase. Lzts1 absence in a defined temporal window
during M phase results in impaired Cdk1/Cdc25C interaction with a consequent drop in Cdk1 activity. During
prophase and metaphase, Lzts1 protein is therefore necessary for maintaining high levels of Cdk1, which, in
turn, are required for proper chromosome alignment and segregation.Cancer Cell 11, 275–289, March 2007 ª2007 Elsevier Inc. 275
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Fez1/Lzts1 Knockout Miceet al., 1998). On the basis of this correlation and through
a positional cloning strategy, we identified a novel putative
tumor-suppressor gene (Ishii et al., 1999), FEZ1/LZTS1
(LZTS1), which maps in this region and whose expression
is altered in different human malignancies (Ishii et al.,
1999; Cabeza-Arvelaiz et al., 2001; Vecchione et al.,
2001, 2002; Toyooka et al., 2002; Ono et al., 2003; Nonaka
et al., 2005). The reintroduction of LZTS1 into Lzts1 null
cancer cells suppresses cell growth, and this suppression
is probably mediated by LZTS1’s interaction with the main
mitotic kinase, p34cdc2 (hereafter referred to as Cdk1) (Ishii
et al., 2001; Vecchione et al., 2002); the majority of cells
are seen at the G2/M phases of the cell cycle (Ishii et al.,
2001; Vecchione et al., 2002).
Cdk1 activity is finely controlled during the G2/M
phases of the cell cycle, and its activity is thought to con-
trol both M phase entry and exit (reviewed in Nigg, 2001).
There are multiple levels of Cdk1 activity regulation, such
as binding with its regulatory subunits (Cyclins A and B),
interaction with CKIs, and phosphorylation and dephos-
phorylation of specific residues (reviewed in Smits and
Medema, 2001). Of the several proteins participating in
the multifaceted Cdk1 regulation, some have been impli-
cated in tumor progression (Carnero, 2002), directly link-
ing proper M phase progression with cell transformation.
However, the involvement of mitotic regulators in cancer
is more difficult to prove since profound alterations of M
phase are often not compatible with eukaryotic life
(Weaver and Cleveland, 2005), a concept in line with the
notion that, up to now, any effort to generate Cdk1 knock-
out (KO) mice has been unsuccessful. Conversely, mild al-
teration of M phase checkpoints often leads to aneuploidy
and cell transformation (Weaver and Cleveland, 2005).
In the present study, we describe the role of the tumor-
suppressor gene Lzts1 in M phase regulation and tumor
progression by utilizing Lzts1 null mice as a model.
RESULTS
Targeted Disruption of the Lzts1Gene Creates a Null
Allele and Favors Spontaneous Tumor Development
The mouse Lzts1 gene was disrupted by the insertion
a neomycin-resistance cassette that replaced the first
Lzts1 exon (Figure 1A). Chimeric males transmitted the
mutated Lzts1 allele through the germline, as demon-
strated by Southern blot analysis of tail DNA (Figure 1B)
and by reverse transcriptase-polymerase chain reaction
(RT-PCR) of Lzts1+/+, Lzts1+/, and Lzts1/ mouse em-
bryo fibroblasts (MEFs) (Figure 1C). Lzts1/ mice arose
at the expected frequency (data not shown). Western
blot analysis of brain lysates from Lzts1+/+, Lzts1+/, and
Lzts1/ mice confirmed the reduction or the absence of
Lzts1 protein (Figure 1D).
Lzts1 heterozygous intercrosses were bred and ob-
served up to 24 months of age. In animals at the age of
8–24 months (average of 16 months), pathological analy-
sis demonstrated that 0 out of 11 Lzts1+/+ mice, 12 out
of 20 Lzts1+/ mice, and 9 out of 9 Lzts1/ mice devel-
oped multiple tumors. The neoplasms in Lzts1/ and276 Cancer Cell 11, 275–289, March 2007 ª2007 Elsevier Inc.Lzts1+/ mice were breast tumors, hepatocellular carcino-
mas, lymphomas, soft tissue sarcomas, and lung adeno-
mas (Figures 1E–1I), a spectrum suggesting that Lzts1
absence affects multiple cell types in vivo. Lymphomas,
hepatocellular carcinomas, and soft tissue sarcomas
developed at a higher penetrance in Lzts1/ than in
Lzts1+/ mice (100%, 75%, and 100% versus 35%,
50%, and 0%, respectively). Penetrance in the other histo-
type was not significantly different. The age of onset of the
tumor was very similar in heterozygous and homozygous
mice (19 ± 4.2 months for Lzts1+/ versus 17 ± 4.2 months
for Lzts1/), suggesting that one Lzts1 allele is not suffi-
cient and does not delay cancer development. To better
address this point, we explored whether the second allele
was lost in heterozygous mice. PCR experiments coupled
with direct sequencing showed that the wild-type (WT)
allele was neither lost nor mutated (data not shown).
Lzts1/ MEFs Progress Normally through the G1,
S, and G2 Phases, but Display an Altered M Phase
Our previous studies indicated that LZTS1 is implicated in
the control of cell cycle progression, since its overexpres-
sion was able to mainly block the cells in the G2/M phases,
and that it probably acts on Cdk1 activity (Ishii et al., 2001;
Vecchione et al., 2002). We used MEFs derived from WT or
KO embryos to verify whether the mechanisms whereby
Lzts1 absence predisposed mice to develop multiple tu-
mors could be linked to its role in the control of cell cycle
progression.
In growth-curve experiments, Lzts1/ MEFs cultured
in complete medium grew more slowly over a 6 day period
when compared to Lzts1+/+ cells (Figure 2A), probably for
an increased apoptosis, as demonstrated by flow cytom-
etry analysis (FACS) (Figure 2B) and TUNEL assay (data
not shown). In order to assess if the reduced cell growth
observed in Lzts1/ MEFs was also due to an altered pro-
gression through the different phases of the cell cycle, we
used cell synchronization to study the transition from the
G1 to S phases and from the S to G2/M phases. Serum
starvation followed by serum stimulation for up to 24 hr in-
dicated that Lzts1+/+ and Lzts1/ MEFs progressed sim-
ilarly from the G1 to S phases and from the S to G2 phases
of the cell cycle (Figure 2C) and demonstrated similar tem-
poral expression and phosphorylation patterns of cell cy-
cle regulatory proteins (Figure 2D). The expression of the
licensing factor Geminin, known to be expressed from
the S to M phases and degraded at the metaphase-
anaphase transition (McGarry and Kirschner, 1998),
peaked in both cell lines 23 hr after serum stimulation;
however, in cells lacking Lzts1, expression decreased
rapidly (Figure 2E).
Using the double-thymidine block coupled with FACS
and western blot analyses, we noted a decreased accu-
mulation in the G2/M phases in Lzts1/ compared to
Lzts1+/+ cells (Figure 3A). The observed differences in
the cell cycle distribution were accompanied by slightly
different expression levels of Cyclin B1 (Figure 3B), which,
in Lzts1+/+ cells, peaked from 4 to 8 hr and decreased
promptly 10 hr after release and, in Lzts1/ cells, rose
Cancer Cell
Fez1/Lzts1 Knockout MiceFigure 1. Lzts1 Knockout Mice Develop Spontaneous Tumors
(A) Targeting of the mouse Lzts1 locus, showing that the genomic region including exons 1 and 2 of the mouse Lzts1 gene (top) were homologously
recombinant with targeting vector (middle), which results in the replacement of part of exon 1 with the neomycin-resistance gene (bottom). Lzts1 cod-
ing was stopped 123 bp downstream of the first methionine. B, BamHI; K, KpnI; BS, Bsp106; N, NotI; H, HindIII; X, XbaI. The 600 bp diagnostic probe
is located outside of the targeting vector sequence.
(B) Southern blot analysis of mouse genomic DNA, digested with XbaI and probed with the diagnostic probe depicted in (A).
(C) RT-PCR analysis showing Lzts1 gene expression in Lzts1+/+, Lzts1+/, and Lzts1/ MEFs as indicated. Actin mRNA expression was used as
a loading control.
(D) Western Blot analysis of Lzts1 expression in brain lysates from Lzts1+/+, Lzts1+/, and Lzts1/ 15-week-old mice. Vinculin expression was used to
normalize the amount of loaded proteins in each lane.
(E) Macroscopic appearance of a primary breast tumor in a Lzts1/ mouse.
(F) Hematoxylin and eosin staining showing ductal differentiation of the breast tumor depicted in (E). The scale bar is 20 mm.
(G) High-grade sarcoma of the tight. The scale bar is 100 mm.
(H) A liver carcinoma is shown (indicated by an asterisk). The scale bar is 20 mm.
(I) Number and incidence of spontaneous tumors in the different genotypes.at 4 hr and remained stable until 10 hr after release (Fig-
ure 3B). These data suggest two possibilities: (1) Lzts1/
cells had a slower S to G2 progression; (2) they had a faster
exit from mitosis.CTo address this point, exponentially growing Lzts1+/+
and Lzts1/ cells were cultured for 1 hr in the presence
of 50-bromodeoxyuridine (BrdU), which was used to label
cells in S phase. After BrdU washout, nocodazole, a drugancer Cell 11, 275–289, March 2007 ª2007 Elsevier Inc. 277
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Fez1/Lzts1 Knockout MiceFigure 2. G1/S and S/G2 Transitions Are Not Affected by Lzts1 Absence in MEFs
(A) Growth curve comparing Lzts1+/+ (black square) and Lzts1/ (gray square) cells over the course of 6 days.
(B) FACS analysis of DNA content of Lzts1+/+ and Lzts1/ MEFs in the logarithmic phase of growth.
(C) Cell cycle distribution of Lzts1+/+ and Lzts1/ MEFs serum starved for 24 hr (starved) and then restimulated with 10% FBS-containing medium
(FCS) for the indicated time.
(D) Western blot analysis of cell cycle-related proteins in Lzts1+/+ and Lzts1/ cells treated as in (C).
(E) Western blot analysis of Geminin expression in Lzts1+/+ and Lzts1/ MEFs serum starved for 24 hr (starved) and then restimulated with 10%
FBS-containing medium for the indicated time. In the lower graph, the expression of Geminin normalized on the levels of vinculin at each time point
is reported.known to block cells in prometaphase, was added, and
cells were collected 3, 12, and 18 hr later. FACS analysis
of BrdU-positive cells showed that Lzts1/ MEFs
progressed normally from the S to G2/M phases of the
cell cycle, but accumulated less efficiently in prometa-
phase (Figure 3C). In fact, after 12–18 hr of nocodazole
treatment, 10% of Lzts1+/+ versus more than 25% of
Lzts1/ MEFs were in the G1/S phases, suggesting that
Lzts1/ cells had a faster exit from mitosis after nocoda-
zole treatment (Figure 3C).
Similar results were obtained by using a double-
thymidine block followed by exposure to Hoechst
33342, which causes a reversible G2 arrest (Tobey et al.,278 Cancer Cell 11, 275–289, March 2007 ª2007 Elsevier Inc.1990). Hoechst treatment increased to 40% in the G2
population of both Lzts1 WT and KO MEFs (Figure 3D). Af-
ter Hoechst washout, the progression through M phase
was completely different since, within 2 hr, the tetraploid
population remained stable in WT cells (41%) and drop-
ped to almost half that (26.8%) in KO fibroblasts
(Figure 3D). Similarly, the G1 population of WT MEFs
was similar in Hoechst-blocked cells and in cells released
for 2 hr (36% versus 40%, respectively), whereas the G1
population almost doubled in KO cells during the same
time frame (39% versus 59% at 0 and 2 hr, respectively)
(Figure 3D). During longer periods of time, both cell lines
returned in G1, consistent with the reversible G2 block
Cancer Cell
Fez1/Lzts1 Knockout MiceFigure 3. Lzts1/ MEFs Displayed Mitotic Defects
(A) Flow cytometry analysis of Lzts1+/+ and Lzts1/ MEFs synchronized at the G1/S transition by a double-thymidine block and released for the
indicated time.
(B) Expression of Cyclin B1 and Cdk1 proteins in cells treated as described in (A).
(C) Evaluation of cell cycle progression in cells labeled with BrdU for 1 hr and then exposed to nocodazole for the indicated time. The percentage of
total or BrdU-labeled cells in each phase of the cell cycle is shown.
(D) Flow cytometry analysis of Lzts1+/+ and Lzts1/ MEFs treated for 10 hr with Hoechst 33342 (left panels, T0) and then released for the indicated
time.induced by Hoechst (Figure 3D). Altogether, these results
indicate that Lzts1 KO MEFs progressed more quickly
through M phase compared to their WT counterparts.
Lzts1/ MEFs Show a Faster M Phase Progression
To better study the role of Lzts1 in M phase progres-
sion, Lzts1 WT and KO mitotic cells were isolated and an-
alyzed for the expression of the MPM2 phosphoprotein(Westendorf et al., 1994; Shuji et al., 2001) and cell cycle
distribution. Similar percentages of mitotic cells were iso-
lated in the two cell lines (Figure 4A). The analysis of DNA
content (Figure 4B) and of MPM2 expression (Figure 4C)
indicated that WT MEFs arrested in prometaphase by
nocodazole completed M phase within 90 min, whereas
KO cells accumulated in G1 within 60 min, consistent
with faster mitotic exit. Immunofluorescence analysisCancer Cell 11, 275–289, March 2007 ª2007 Elsevier Inc. 279
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Fez1/Lzts1 Knockout MiceFigure 4. Lzts1/ MEFs Displayed a Faster M Phase Progression
(A) Expression of the mitotic phosphoprotein MPM2 in proliferant and mitotic shake-off Lzts1+/+ and Lzts1/ MEFs.
(B) Flow cytometry analysis of Lzts1+/+ and Lzts1/ MEFs isolated by mitotic shake-off (left panels) and released for 60 min (right panels).
(C) Expression of the mitotic phosphoprotein MPM2 in cells collected by mitotic shake-off (0) and released for the indicated times.
(D and E) Quantification of (D) total mitosis length and of (E) time spent in each mitotic phase in Lzts1+/+ and Lzts1/ MEFs, evaluated by video time-
lapse microscopy. Results (mean ± SD) are representative of eight mitotic cells (n = 8) followed independently.
(F) Flow cytometry analysis of Lzts1+/+ and Lzts1/ MEFs treated with 100 nM taxol or 1 mM nocodazole, as indicated.
(G) Hoechst nuclear staining of Lzts1+/+ (left panels) and Lzts1/ (right panels) MEFs treated for 18 hr with 100 nM taxol. Representative fields are
shown. Scale bars are 20 mm.
(H) Quantification of mitotic nuclei by using Hoechst nuclear staining in cells treated as indicated. Data represent the mean of three independent
experiments on two different MEF populations.performed 90 min after the release from the nocodazole
block demonstrated that the majority of WT MEFs still
had the mid-body, suggesting that they were between280 Cancer Cell 11, 275–289, March 2007 ª2007 Elsevier Inc.telophase and cytokinesis; however, at the same time
point, almost all KO MEFs had already divided
(Figure S1A).
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Fez1/Lzts1 Knockout MiceFigure 5. Lzts1 Absence Results in Decreased Cdk1 Activity and Chromosome Missegregation
(A) Cdk1-associated kinase activity in MEFs collected by mitotic shake-off (0) and released for the indicated times. The levels of Cdk1 are shown in the
lower panels.
(B) Expression of Cyclin B1 and Cdk1 proteins and Cdk1-associated kinase activity in cells treated as indicated. Histone H1 (HH1) and vinculin were
used to normalize the kinase assay and the proteins loaded on the blot, respectively. The 0* lane is the negative control of the kinase reaction in which
the immunoprecipitated proteins have not been added.
(C) Immunofluorescence analysis of Lzts1+/+ and Lzts1/ mitotic cells stained for a-tubulin (green) and P.I. (red). A representative confocal section
of a normal telophase in Lzts1+/+ cells (upper panel) and of a telophase with missegregated (lagging) chromosomes (yellow arrows in the lower panel)
in Lzts1/ cells are shown. The scale bar is 19.5 mm.
(D) Quantification of mitosis presenting missegregated chromosomes in Lzts1+/+ and Lzts1/ MEFs examined 8 hr after the double-thymidine block.
n is the total number of mitoses analyzed.
(E) Flow cytometry analysis of Lzts1+/+ and Lzts1/ MEFs treated with 1 mM nocodazole, as indicated. The percentage of the 8n population, repre-
senting the mean of two independent experiments on two different MEF populations, is reported.Most of the reported experiments were conducted
by utilizing nocodazole to synchronize cells in prometa-
phase. Since nocodazole treatment by itself has an effect
on M phase length (Cimini et al., 2003), we decided to
observe M phase progression in undisturbed cells by
using video time-lapse microscopy. Cells were both
double-thymidine blocked or left untreated, and they
were followed for up to 12 hr by video microscopy, as
described in Experimental Procedures. The analysis of
eight WT and eight KO MEFs confirmed that in the
absence of drug treatment Lzts1/ MEFs had a faster
prophase-telophase transition (Figures 4D and 4E) and
demonstrated that the major difference between Lzts1+/+
and Lzts1/ cells was indeed the time needed to com-
plete prophase (Figure 4E).
We next tested the effects of two different compounds
able to block cells in prometaphase on Lzts1 WT and KO
MEFs. Both nocodazole- or taxol-treated Lzts1/ cells
failed to properly arrest in prometaphase (Figure 4F), and
taxol- or nocodazole-treated Lzts1/ MEFs displayed a
lower percentage of abnormal mitotic figures (Blajeski
et al., 2002) compared to Lzts1+/+ cells (Figures 4G and4H), consistent with an altered drug-induced M phase
block.
Lzts1 Contributes to the Regulation of Cdk1
Activity during Mitosis
Once it had been defined that Lzts1 absence principally
affects the transition from prophase to anaphase, we
tested whether it influenced Cdk1 activity during M phase.
To this purpose, Cdk1 was immunoprecipitated from
Lzts1+/+ and Lzts1/ MEFs isolated by mitotic shake-off
or treated with nocodazole and taxol, and its kinase activ-
ity was tested in an in vitro assay. Interestingly, levels of
phosphorylated histone-H1 by Cdk1 were lower in mitotic
Lzts1/ MEFs (Figure 5A) and in nocodazole- or taxol-
treated Lzts1/ cells (Figure 5B). Similarly, in MEFs
released from serum starvation, Cyclin B1 activity (Fig-
ure S2A; see the Supplemental Data available with this
article online) and, in nocodazole-synchronized cells,
Cdk1 activity (Figure S2B) dropped sooner in Lzts1/
cells than in their WT counterparts. Altogether, these
data indicate that, during mitosis, Lzts1 absence resultedCancer Cell 11, 275–289, March 2007 ª2007 Elsevier Inc. 281
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Fez1/Lzts1 Knockout MiceFigure 6. Loss of Lzts1 Impairs the Cdk1/Cdc25C Interaction in Mitotic Cells
(A) Western blot analysis of Cdc25C, Cdk1, and Cdk1-pY15 proteins in asynchronously growing (Async.) or in mitotic (Mitotic) Lzts1+/+ and Lzts1/
MEFs.
(B) Western blot analysis of Cdc25C and Cdk1 in lysates from Lzts1+/+ and Lzts1/ MEFs as in (A), immunoprecipitated with anti-Cdk1 antibody.
(C) Western blot analysis of hLzts1, hCdc25C, and hCdk1 in lysates (right panels) and Flag-IP (left panels) in 293 cells transfected with Flag-hCdc25C
and increasing amounts of V5-hLzts1.
(D) Expression of hLzts1 and hCdc25C proteins in 293 cells transfected with the indicated vectors and treated with nocodazole for 6 hr in the presence
or absence of the proteasome inhibitor MG132 (25 mM). Expression of Ha-Ub and 14-3-3 proteins was used as loading control.
(E) Cell lysates described in (D) were immunoprecipitated with an anti-Flag antibody and were analyzed for Ha-Ub and Cdc25C expression.
(F) 293 cells treated as in (D) were isolated by mitotic shake-off, and cell lysates were immunoprecipitated with an anti-Flag-HA antibody and were
analyzed for Cdc25C expression.
(G) Proteins from Lzts1+/+ and Lzts1/ fibroblasts transduced with HA-Ub and hCdc25C retroviruses and then isolated by mitotic shake-off were
immunoprecipitated with either an anti-Cdc25C or an anti-HA antibody and probed for HA-Ub or Cdc25C expression as indicated.
(H) Proteins from Lzts1+/+ and Lzts1/ fibroblasts treated as in (G) were immunoprecipitated and probed with an antibody specific for the Cdc25C
phosphatase. An asterisk indicates nonspecific bands.282 Cancer Cell 11, 275–289, March 2007 ª2007 Elsevier Inc.
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Fez1/Lzts1 Knockout Micein a lower Cdk1 activity coupled with a faster prophase
progression.
The time to complete mitosis represents an important
variable in the execution of proper DNA separation (Cimini
et al., 2003), and it has been demonstrated that decreas-
ing Cdk1 activity in mitosis-arrested cells results in prompt
mitotic exit accompanied by defects in DNA segregation
(Seong et al., 2003; Niiya et al., 2005; Potapova et al.,
2006).
We looked at the functional consequences of the faster
mitotic exit accompanied by the lower Cdk1 activity ob-
served in Lzts1/ cells. Immunofluorescence analysis
showed a 5-fold increase (4.5% in Lzts1+/+ versus
26.1% in Lzts1/ MEFs) in the number of cells containing
lagging chromosomes during undisturbed mitosis in the
absence of Lzts1 (Figures 5C and 5D; Figure S1). This
observation was further confirmed by the 4.5-fold in-
crease in the percentage of cells with micronuclei in
Lzts1/ MEFs released after the thymidine block (Figures
S1C and S1D). Moreover, after 3 or 4 days of nocodazole
treatment, Lzts1/ cells showed an increased hypertetra-
ploid population (Figure 5E).
Overall, these data demonstrated that Lzts1 absence
shortened M phase length and determined a decrease of
Cdk1 activity during mitosis accompanied by increased
chromosomes missegregation.
Lzts1 Is Necessary for Proper Cdk1/Cdc25C
Interaction during Mitosis
How Lzts1 absence decreases Cdk1 activity as well as
whether reduced kinase activity was responsible for the
mitotic defects were investigated. Cdk1 activity is regu-
lated by cyclin binding and phosphorylation of specific
residues. Among the latter, a key role has been proposed
for T14/Y15 phosphorylation by Wee1/Myt kinases and for
dephosphorylation by Cdc25 phosphatases (Smits and
Medema, 2001). Neither Cdk1 nor Cyclin B1 levels were
significantly different (Figures 2D, 3B, and 5B) in WT and
KO cells. Conversely, a higher Cdk1-pY15/Cdk1 ratio (Fig-
ure 6A) accompanied by lower levels of endogenous
Cdc25C phosphatase was observed in mitotic Lzts1/
MEFs (Figure 6A). Importantly, the different Cdc25C ex-
pression resulted in lower levels of endogenous Cdc25C
associated with endogenous Cdk1 in mitotic Lzts1/
MEFs (Figure 6B), evidence that could explain the higher
Cdk1-pY15 phosphorylation and the lower Cdk1 activity.
A functional link between Lzts1 and Cdc25C expression
was sought by transfecting 293 cells that were nocoda-
zole synchronized in prometaphase with Flag-hCdc25C
alone or with increasing amounts of V5-hLzts1. hCdc25C
and hLzts1 coprecipitated (Figure 6C), and the increased
expression of hLzts1 resulted in increased interaction be-
tween hCdc25C and endogenous Cdk1 (Figure 6C, lowerpanel). It has been proposed that in G2/M-arrested cells,
hCdc25C may be efficiently ubiquitinated (Chen et al.,
2002). To verify whether Lzts1 expression might control
Cdc25C ubiquitination, cells were transfected with Flag-
hCdc25C with or without V5-hLzts1 and were then noco-
dazole synchronized in the presence or absence of the
proteasome inhibitor MG132. MG132 did not increase
hCdc25C levels when hLzts1 was overexpressed, but it
did increase levels in its absence (data not shown and
Figure 6D). The same experiment was repeated with inclu-
sion of a plasmid encoding an HA-tagged ubiquitin (HA-
Ub) (Figures 6D and 6E). Data show that overexpression
of Lzts1 reduced Cdc25C ubiquitination in 293 cells
treated with nocodazole (Figure 6E). Moreover, 293 cells,
transfected as described above, were isolated by mitotic
shake-off, and cell lysates were immunoprecipitated
with an anti-HA antibody to collect the ubiquitinated pro-
teins. In mitotic cells, Lzts1 expression strongly decreased
the ubiquitinated levels of Cdc25C (Figure 6F). In order to
verify these observations in a more physiological system,
hCdc25C and HA-Ub were retrovirally transduced into
Lzts1+/+ and Lzts1/ fibroblasts treated or not treated
with nocodazole in the presence or absence of MG132. In-
creased Cdc25C ubiquitination was observed in Lzts1/
cells compared to parental cells (Figures 6G and 6H).
To confirm the physiological significance of the de-
scribed interaction, we precipitated the endogenous
Cdc25C protein from mitotic or exponentially growing
293 cells known to express high levels of Lzts1 (Ishii
et al., 2001). In these conditions, endogenous Lzts1 read-
ily associated with Cdc25C protein, preferentially in mi-
totic cells (Figure 6I). Moreover, analysis of the stability
of the endogenous Cdc25C protein, evaluated by cyclo-
heximide treatment, showed a decrease in Lzts1/ only
when cells were arrested in prometaphase, not when cy-
cloheximide was added after the cells had returned to
G1 phase (Figure 6J). In addition, we examined proteins
from the mitotic fraction of a panel of human carcinoma
cell lines that showed low Lzts1 expression to be associ-
ated with low levels of Cdc25C protein (Figure S3A) and
with an increased phosphorylation of Cdk1 on Y15 when
compared with normal mammary epithelial cells or 293
cells (Figures S3B and S3C). Importantly, reintroduction
of Lzts1 in several Lzts1-deficient cells by using different
technical approaches resulted in increased levels of
Cdc25C only when the cells were isolated by mitotic
shake-off (Figure S4).
Accordingly, hLzts1 re-expression in Lzts1/ cells in-
creased levels of Cdc25C protein (Figure 7A) and de-
creased levels of phosphorylated Cdk1-pY15 in mitotic
cells (Figure 7A). Importantly, Lzts1 re-expression in
Lzts1/ MEFs rescued the sensitivity to taxol and noco-
dazole (Figures 7D and 7E), indicating that the observed(I) Proteins from 293T cells isolated from exponentially growing or mitotic cells were immunoprecipitated with an antibody specific for the Cdc25C
phosphatase (or control antibody) and were probed for Lzts1 (upper panel) and Cdc25C (lower panel).
(J) Cdc25C stability in mitotic (left panels) or G1 (right panels) cells. The protein stability of Cdc25C was analyzed in prometaphase cells (nocodazole
arrested) and in asynchronous cells by treatment with cycloheximide for the indicated time points (min). Quantification of protein expression was ob-
tained by scanning the blots with the Biorad GS100 scanner interfaced with the Quantity One software.Cancer Cell 11, 275–289, March 2007 ª2007 Elsevier Inc. 283
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Fez1/Lzts1 Knockout MiceFigure 7. Regulation of Cdc25C Activity by Lzts1 Is Necessary for Proper Mitotic Progression
(A) Western blot analysis of Cdk1-pY15, Cdk1, Cdc25C, Lzts1, and vinculin (loading control) proteins in mitotic Lzts1/ MEFs transduced with an
empty vector or with a vector encoding for the Lzts1 protein. Lysates were collected 0 or 30 min after the mitotic shake-off.
(B) Western blot analysis of Cdc25C, Lzts1, and vinculin (loading control) proteins in Lzts1/ MEFs transduced with the indicated vectors. Mouse
brain lysate was used as a positive control for Lzts1 expression.
(C) RT-PCR analysis of Cdk1AF expression in Lzts1/ MEFs transduced as indicated. The transduced DNA plasmids (vector) were used as positive
controls.
(D and E) Evaluation of mitotic nuclei in Lzts1/ MEFs transduced as indicated. Typical fields of Hoechst nuclear staining are shown in (E), and the
mean of three independent experiments is reported in (D).
(F) Western blot analysis of Cdk1 and Cdk1-pY15 expression in Lzts1+/+ MEFs treated for 1 hr with DMSO (NT), NSC, or Na3VO4 and then with taxol for
18 hr.
(G and H) Evaluation of mitotic nuclei in Lzts1+/+ MEFs treated as in (F). Data (mean ± SD) represent the mean of a least three independent experiments
performed in duplicate.
(I) Flow cytometry analysis of Lzts1+/+ and Lzts1/ MEFs treated with vehicle (DMSO) or 10 mM NSC for 1 hr and then, after the NSC washout,
exposed to 100 nM taxol for the indicated time. Scale bars are 20 mm.284 Cancer Cell 11, 275–289, March 2007 ª2007 Elsevier Inc.
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Fez1/Lzts1 Knockout Micedifferences between Lzts1 WT and KO cells could be as-
cribed to the absence of Lzts1 protein.
To further test the role of Cdc25C in the mitotic pheno-
type observed in Lzts1 null fibroblasts, we retrovirally
transduced Lzts1/ cells with Cdc25C (Figure 7B) or
with a nonphosphorylable form of Cdk1 protein (Cdk1AF)
(Figure 7C). In the absence of Lzts1, both Cdc25C and
Cdk1AF expression resulted in a reacquisition of sensitiv-
ity to a taxol- and nocodazole-induced M phase block
(Figures 7D and 7E). Overall, these data suggest that the
Lzts1/Cdk1/Cdc25C pathway represents a key control
for the proper execution of M phase.
To verify whether Cdc25C deregulation in WT cells
could recapitulate the phenotype observed in Lzts1 null
cells, we used the Cdc25C inhibitor NSC 663284 (NSC)
(Chao et al., 2004; Han et al., 2004). Like Lzts1 null
MEFs, Lzts1+/+ MEFs treated with NSC for 1 hr and then
washed and exposed to taxol showed increased Cdk1-
pY15 phosphorylation levels (Figure 7F) and overcame
the taxol-dependent M phase block (Figures 7G–7I). The
nonspecific phosphatase inhibitor sodium orthovanadate
(NaVO4) had no effect on either Cdk1-pY15 phosphoryla-
tion or taxol-induced mitotic block (Figures 7F and 7G).
Lzts1-Deficient MEFs Are Prone to Transformation
How can the observed mitotic defects be linked to the in-
creased tumor incidence noted in Lzts1 KO mice? We
speculated that since Lzts1/ MEFs showed altered
chromosome segregation (Figure 5C; Figure S1), they
could be more prone to transformation due to the accu-
mulation of genetic abnormalities. To test this hypothesis,
WT and KO Lzts1 MEFs were retrovirally infected with
a Ha-Ras (V12) vector (Figure S5A), selected in hygromy-
cin, and assayed for the ability to form colonies in soft
agar. Only Lzts1/ MEFs formed colonies (Figure S5B),
an effect independent of the silencing of the p19Arf tu-
mor-suppressor gene (Figure S5), confirming that Lzts1
absence conferred a tumor-prone phenotype to mouse
cells.
High Incidence of NMBA-Induced Forestomach
Tumors in Lzts1-Deficient Mice
We also tested whether this observation could be recapit-
ulated in in vivo experiments. Since the LZTS1 gene is
often downregulated in esophageal carcinomas (Ishii
et al., 1999), and since epidemiological studies have
linked exposure to N-nitrosomethylbenzylamine (NMBA)
with an increased incidence of esophageal cancer
(Yang, 1980; Magee, 1989), NMBA treatment was used
to determine whether Lzts1 modulates carcinogen-
induced malignancy development. A total of 6 weeks after
NMBA administration, all 20 Lzts1/ mice (100%) and
all 33 Lzts1+/ mice (100%) developed multiple tumors
of the forestomach (Figure 8), whereas only 5 of 30
Lzts1+/+ mice (17%) developed tumors (Lzts1+/+ versus
Lzts1/, p < 0.001; Lzts1+/+ versus Lzts1+/, p < 0.001).
Histological sections showed an array of lesions
typically seen in NMBA-treated animals, including hy-
perplasia, focal hyperplastic lesions, papillomas, andcarcinomas. Lzts1/ and Lzts1+/ mice developed inva-
sive carcinoma of the forestomach at a high frequency,
while Lzts1+/+ mice mostly showed thin and regular epi-
thelia (Figure 8). All Lzts1+/ mice retained the WT allele
(Figure 8) that was negative for mutations (data not
shown), suggesting haploinsufficiency of Lzts1, as sup-
ported by the fact that Lzts1 heterozygous mice devel-
oped spontaneous tumors retaining the normal allele.
DISCUSSION
The present study demonstrates how inactivation of one
or both Lzts1 alleles causes an increased incidence of ei-
ther spontaneous or carcinogen-induced tumors in mice.
Figure 8. Loss of Lzts1 Enhances NMBA-Induced Forestom-
ach Carcinogenesis in Mice
(A) Left panels: gross morphology of the forestomach and SCJ in
Lzts1+/+, Lzts1+/, and Lzts1/ mice (top to bottom, 353). Middle
panels: hematoxylin and eosin stained forestomach sections. Normal
epithelium is shown in Lzts1+/+; early infiltrating carcinomas and infil-
trating carcinomas are shown in Lzts1+/ and Lzts1/ mice. The scale
bars are 100mm in upper panel and 20mm in lower panels. Right panels:
retention of the remaining WT allele in a tumor from heterozygous mice.
(B) Number and incidence of induced tumors in the different
genotypes.Cancer Cell 11, 275–289, March 2007 ª2007 Elsevier Inc. 285
Cancer Cell
Fez1/Lzts1 Knockout MiceThe development of spontaneous tumors from different
organs suggests that Lzts1 absence interferes with impor-
tant pathways in normal cell homeostasis.
Besides the appearance of spontaneous tumors of dif-
ferent origins, we demonstrated that the absence of en-
dogenous Lzts1 results in increased tumor susceptibility
of the forestomach after NMBA treatment (present work)
and of the bladder after N-butyl-N-(4-hydroxybutyl) nitro-
samine (BBN) administration (A.V. and C.M.C., unpub-
lished data), further suggesting that Lzts1 absence sensi-
tizes multiple tissues to carcinogenesis. In both cases,
loss of one Lzts1 allele effectively predisposes mice to car-
cinogenesis, since, in fact, no loss of the WT Lzts1 allele or
mutation in the Lzts1 coding region was found. Therefore,
the Lzts1 gene could be haploinsufficient in tumor sup-
pression, as already demonstrated for other tumor-
suppressor genes, like p53 (Venkatachalam et al., 1998),
p27kip1 (Fero et al., 1998), or Pten (Kwabi-Addo et al.,
2001).
The tumor-prone phenotype of Lzts1 KO mice is consis-
tent with the role of Lzts1 protein in the control of M phase
progression described here. Aneuploidy has been strictly
linked to human cancer, and it is increasingly accepted
that weakened M phase checkpoints likely result in aneu-
ploidy and tumor progression (Weaver and Cleveland,
2005). The finding in Lzts1 null cells of a higher number
of missegreagated chromosomes is consistent with the
Lzts1 tumor-suppressor role in several tissues in vivo.
The relative late onset of spontaneous tumors observed
in Lzts1 KO mice could be explained by the high apoptotic
rate of Lzts1-deficient MEFs. Accordingly, in spleens of 5-
to 6-month-old mice (n = 4 WT and 5 KO), there is a 5-fold
increase in the amount of the caspase-3-negative nuclear
fragment (20.25 ± 4.2 versus 4.4 ± 2 3 high-power field
[HPF]; n = 100 HPF), which represents engulfed apoptotic
bodies or cells that died as a result of mitotic catastrophe
after unsuccessful cell division (Figure S6).
The present work demonstrates that Lzts1 protein ex-
pression is critical for normal mitosis progression. Lzts1
absence shortens the mitotic division time and causes im-
proper chromosome segregation, lowering Cdk1 activity
through Cdc25C destabilization. The classical view of M
phase entrance and progression implicates a central role
for Cdk1 and Cdc25C, with high Cdk1 activity necessary
for the proper execution of M phase (reviewed in Jackson,
2006). However, several experimental evidences suggest
that the loss of Cdk1 activity primarily drives the exit from
mitosis, data arguing that Cdk1 inactivation serves as
a mechanism for ensuring the correct timing of mitosis
exit (Potapova et al., 2006; Cross et al., 2005; Parry and
O’Farrell, 2001; Sigrist et al., 1995; Chang et al., 2003).
The activity of Cdk1 upon mitosis entry is higher than
what is needed to maintain the M phase. Such a hysteric
loop likely depends on Cdk1 phosphorylation levels,
rather than on cyclin expression (Sha et al., 2003). Accord-
ingly, the depletion of Greatwall kinase from Xenopus mi-
totic extract induced a prompt exit from M phase with an
increase of Cdk1-pY15 phosphorylation, likely the result
of Cdc25C inactivation rather than Cyclin B1 degradation286 Cancer Cell 11, 275–289, March 2007 ª2007 Elsevier Inc.(Yu et al., 2006). This observation is consistent with
the fact that pharmacological inhibition of Cdk1 in mitotic
cells determines a prompt exit from mitosis, even in
the presence of proteasome inhibitors or prometaphase
actin drugs (Seong et al., 2003; Niiya et al., 2005;
Potapova et al., 2006; Vassilev et al., 2006). Since Cyclin
B1 degradation is necessary for the onset of anaphase
(Chang et al., 2003) and starts as soon as the chromo-
somes align at the metaphase plate (Clute and Pines,
1999), decreased Cdk1 activity via changes in its inhibitory
phosphorylation could lead to mitotic exit in the window
between prophase and metaphase, during which Lzts1
seems to principally act.
It has recently been reported that Cdc25 phosphatases
play different roles in the execution of proper M phase pro-
gression: Cdc25A and Cdc25B are necessary for M phase
entry, and Cdc25C plays a more prominent role in the
proper execution of prophase (Lindqvist et al., 2005).
This finding is in agreement with our observation that the
Lzts1/Cdc25C interaction mainly impairs prophase length
rather than M phase entrance. Whether the Lzts1/Cdc25C
interaction is dependent on the presence of other proteins
or on Lzts1 and/or Cdc25C phosphorylation is an issue
that will be investigated in future studies. However, the
data presented here add another piece in the complex
regulation of mitosis progression and suggest that the
control of protein degradation during M phase governs
the progression from prophase to metaphase, thus going
beyond the regulation of the anaphase-cytokinesis transi-
tion driven by the activation of the Anaphase Promoting
Complex.
Collectively, our data and the current literature suggest
that decreasing Cdk1 activity in interphase cells may re-
sult in the G2 block of the cell cycle, whereas decreasing
Cdk1 activity in M phase before the establishment of the
metaphase plate may cause a faster prometaphase pro-
gression and mitotic exit, as seen in Lzts1/ cells. Inter-
estingly, this hypothesis has recently been experimentally
proven in human cell lines by using a new selective Cdk1
inhibitor (Vassilev et al., 2006).
In the present work, we show that Lzts1 contributes to
the maintenance of high levels of Cdk1 activity during
M phase, preventing chromosomes missegregation. This
important function of Cdk1 has been recently demon-
strated by the use of Cdk1-specific inhibitors. The sudden
drop of Cdk1 activity in prometaphase-arrested cells re-
sults in chromosomes missegregation and the formation
of aneuploid progeny (Seong et al., 2003; Vassilev et al.,
2006).
In complete agreement with this view, KO of the
RASSF1A protein shortened prometaphase length by pre-
maturely inducing Cyclin B1 degradation and led to the
appearance of misaligned chromosomes. As a conse-
quence, RASSF1A null cells are more prone to cell trans-
formation (Song et al., 2004). Thus, two independent stud-
ies support the hypothesis that there may exist proteins
(i.e., Lzts1 and RASSF1A) able, by different mechanisms,
to ensure that Cdk1 activity remains high until the meta-
phase plate is formed. The absence of such regulators
Cancer Cell
Fez1/Lzts1 Knockout Miceresults in a similar tumor-prone phenotype linked to chro-
mosome missegregation, suggesting that a fine regulation
of Cdk1 activity is necessary not only for M phase en-
trance and exit, but also for the progression from prome-
taphase to metaphase. Accordingly, our preliminary data
suggest that Lzts1 overexpression in mammary carci-
noma cells leads to an increased number of M phase-
arrested cells that eventually die by apoptosis or mitotic
catastrophe for an unsuccessful cell division (G.B. and
C.M.C., unpublished data). Similarly, RASSF1A overex-
pression results in M phase block at prometaphase, fol-
lowed by cell death (Song et al., 2004). The involvement
in this type of regulation of two proteins that regulate pro-
tein degradation and bind the microtubules, Lzts1 (Ishii
et al., 2001) and RASSF1A (Song et al., 2004), suggests
that the spatial organization of the cyclin/Cdk1 complex
is also important to achieveme proper activation of the
complex, an issue that needs further work to be clarified.
In conclusion, our work points to Lzts1 as an important
player in the execution of normal M phase progression.
Moreover, we show that the absence of Lzts1 leads to im-
paired chromosome segregation, cell transformation, and
cancer progression, and that mice lacking Lzts1 are an im-
portant tool by which to study mitosis progression, cancer
etiology, and resistance to anticancer therapy.
EXPERIMENTAL PROCEDURES
Mouse Lzts1 Gene Targeting and Mating
Generation of knockout mice for Lzts1 is better described in Supple-
mental Experimental Procedures.
Expression Vectors
The human CDC25C cDNA, inserted in the pOTB7 vector, was pur-
chased from ‘‘MAMMALIAN GENE COLLECTION’’ American Type
Culture Collection. The CDC25C cDNA was subcloned in the pFlag-
CMV 6a expression vector (Sigma). For retroviral expression, LZTS1,
CDC25C, and CDK1AF cDNAs were cloned in pMSCV-Puro vector
(Clontech) without any tag. The pHA-Ubiquitin, the pMSCV-Ha-Ras,
and the pHA-CDK1AF expression vectors are kind gifts of Prof.
A. Morrione, R. Baserga, and G. Draetta, respectively.
Cell Cultures and Treatments
MEFs were derived from 13.5-day-old embryos as previously de-
scribed (McCurrach and Lowe, 2001). Briefly, after removal of the
head and internal organs, embryos were rinsed with phosphate-
buffered saline (PBS), minced, and resuspended in DMEM containing
10% FBS and 2 mM glutamine, 0.1 mM MEM nonessential amino
acids, and 100 IU/ml penicillin and 100 mg/ml streptomycin. Cell media
and reagents were obtained from GIBCO-BRL, except where noted.
Cells from single embryos were plated into one 100 mm culture dish
(Falcon) and incubated at 37C in a 5% CO2-humidified chamber. Plat-
ing after disaggregation of embryos was considered passage 0, and
the first replating 3 days later was considered passage 1. All of the
experiments were performed by using cells between passages 2 and
10 from three different batches. Genotypes of MEFs were verified by
RT-PCR and Southern blot analysis.
For retroviral transduction of proliferating primary MEFs, high-titer
viruses were produced from EcoPack293 (Clontech) transfected with
pMSCV vectors by the calcium-phosphate precipitation technique.
Stable, mass-transduced MEF populations were selected in Hygrom-
ycin B (400 mg/ml) or Puromycin (1.5 mg/ml), and the effective expres-
sion of the transduced proteins was always confirmed by western blotCanalysis and by RT-PCR with the appropriate MSCV primers
(Clontech).
MEF synchronization in the different phases of the cell cycle as well
as treatments are better described in Supplemental Experimental
Procedures.
Immunoprecipitation, Immunoblotting,
and Immunocytochemistry
Procedures for protein analysis by immunoprecipitation, immunoblot-
ting, and immunocytochemistry are described in Supplemental Exper-
imental Procedures and were essentially performed as previously
described (Baldassarre et al., 2005).
Time-Lapse Experiments
Monitoring of cell mitosis was carried out on double-thymidine-
blocked and nonblocked cells. For the double-thymidine block,
30%–40% confluent cells, seeded in 35 mm diameter Petri dishes,
were incubated with 2 mM thymidine for 14–16 hr at 37C. After incu-
bation, cells were rinsed with PBS and incubated with thymidine-free
medium for 10 hr. Then, cells were split 1:2 and reincubated with
2 nM thymidine for 18 hr. After 5 hr of block, cell mitosis was followed
with time-lapse cinematography, by using Image Analysis Software
(Discovery-1, Universal Imaging, USA). Nonblocked cells were starved
overnight with DMEM-0.1% FBS before time-lapse analysis.
The apparatus for time-lapse experiments consisted of an inverted
microscope (IX50 Olympus), a CCD coolsnap camera (RS Photome-
trix, USA), an x-y-z computer-controlled stage, PROSCAN (Prior,
USA), and a mini-incubator set on the stage. The camera and the com-
puterized stage were synchronized by a specific code to follow several
cells in the same experiment. Cells were observed for 7–12 hr, and im-
ages were acquired every 1 or 2 min. Movies were realized from the ac-
quired images and were analyzed by Metamorph off-line software.
Animal Experiments
Eleven- to twelve-week-old Lzts1+/, Lzts1/, or Lzts1+/+ mice, which
were produced in the Thomas Jefferson University animal facility, were
given two intragastric doses of NMBA (Ash Stevens, Inc.) over the
course of 1 week at 2 mg/kg body weight. All mice were sacrificed
6 weeks after NMBA doses. Animal experiments were conducted after
approval of the Institutional Animal Care and Use Committee, Thomas
Jefferson University.
Tumor Microdissection and DNA and RNA Analysis
Tumor microdissection and DNA amplification were performed as de-
scribed previously (Bai et al., 2003), after minor modification. Briefly,
15 mm sections adhered on slides were deparaffinized, and the lesions
were scraped off the sections so that they could be separated from
normal tissue. The material obtained was then digested in DNA diges-
tion buffer with the addition of 200 mM proteinase K. The murine Lzts1
contains three coding exons that were amplified and sequenced with
three pairs of primers (available upon request). PCR products were
subjected to direct sequencing after purification through a QIAquick
column (QIAGEN). RT-PCR was performed with a Superscript cDNA
synthesis system (GIBCO-BRL). PCR amplification was performed
with primers (available upon request) corresponding to the 50 and 30
margins of exon 1.
The cDNA was amplified by using glucose-3-phosphate dehydroge-
nase primers (Clontech) as controls.
Statistical Evaluation
A biostatistic program (GraphPad Software, Inc., San Diego, CA) was
used for statistical analysis. Tumor incidence differences were ana-
lyzed by a two-sided Fisher’s exact test. All statistical tests were two
sided and were considered to be statistically significant at p < 0.05.ancer Cell 11, 275–289, March 2007 ª2007 Elsevier Inc. 287
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The Supplemental Data include Supplemental Experimental Proce-
dures and six supplemental figures and are available at http://www.
cancercell.org/cgi/content/full/11/3/275/DC1/.
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